Book Text

REFERENCES

151. Barin F, Goudeau A, Denis F, et al: Immune response in neonates to hepatitis B vaccine. Lancet 1:251–253, 1982.

152. Njoku D, Laster MJ, Gong DH, et al: Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: Association between protein acylation and hepatic injury. Anesth Analg 84:173–178, 1997.

153. Eger EI, Smuckler EA, Ferrell LD, et al: Is enflurane hepatotoxic? Anesth Analg 65:21–30, 1986.

154. Sadove MS, Reis L, Askin SH, et al: Hepatitis after use of two different fluorinated anesthetic agents. Anesth Analg 53:336, 1974.

155. Sigurdsson J, Hreidarsson AB, Thjodleifsson B: Enflurane hepatitis: A report of a case with a previous history of halothane hepatitis. Acta Anaesthesiol Scand 29:495–496, 1985.

156. Christ DD, Kenna JG, Kammerer W, et al: Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 69:833–838, 1988.

157. Stoelting RK, Blitt CD, Cohen PJ, Merin RG: Hepatic dysfunction after isoflurane anesthesia. Anesth Analg 66:147–153, 1987.

158. Brunt EM, White H, Marsh JW, et al: Fulminant hepatic failure after repeated exposure to isoflurane anesthesia: A case report. Hepatology 13:1017–1021, 1991.

159. Turner GB, O'Rourke D, Scott GO, Beringer TR: Fatal hepatotoxicity after re-exposure to isoflurane: A case report and review of the literature. Eur J Gastroenterol Hepatol 12:955–959, 2000.

160. Njoku DB, Shrestha S, Soloway R, et al: Subcellular localization of trifluoroacetylated liver proteins in association with hepatitis following isoflurane. Anesthesiology 96:757–761, 2002.

161. Jones RM, Koblin DD, Cashman JN, et al: Biotransformation and hepato-renal function in volunteers after exposure to desflurane (I-653). Br J Anaesth 64:482–487, 1990.

162. Wrigley SR, Fairfield JE, Jones RM, Black AE: Induction and recovery characteristics of desflurane in day case patients: A comparison with propofol. Anaesthesia 46:615–622, 1991.

163. Berghaus TM, Baron A, Geier A, et al: Hepatotoxicity following desflurane anesthesia. Hepatology 29:613–614, 1999.

164. Molina DM, Rowland FS: Stratospheric sink for chlorofluoromethanes: Chlorine atom-catalyzed destruction of ozone. Nature 249:810–812, 1974.

165. U.S. Environmental Protection Agency: Report no 53. Federal Register, 1988.

166. Harris JW, Pohl LR, Martin JL, Anders MW: Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trifluoroethane. Proc Natl Acad Sci U S A 88:1407–1410, 1991.

167. Lind RC, Gandolfi AJ, Hall PM: Biotransformation and hepatotoxicity of HCFC-123 in the guinea pig: Potentiation of hepatic injury by prior glutathione depletion. Toxicol Appl Pharmacol 134:175–181, 1995.

168. Rusch GM, Trochimowicz HJ, Malley LJ, et al: Subchronic inhalation toxicity studies with hydrochlorofluorocarbon 123 (HCFC 123). Fundam Appl Toxicol 23:169–178, 1994.

169. Dekant W: Toxicology of chlorofluorocarbon replacements. Environ Health Perspect 104(Suppl 1):75–83, 1996.

170. Hoet P, Graf ML, Bourdi M, et al: Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet 350:556–559, 1997.

171. Watanabe K, Hatakenaka S, Ikemune K, et al: [A case of suspected liver dysfunction induced by sevoflurane anesthesia.] Masui 42:902–905, 1993.

172. Shichinohe Y, Masuda Y, Takahashi H, et al: [A case of postoperative hepatic injury after sevoflurane anesthesia.] Masui 41:1802–1805, 1992.

173. Bruun LS, Elkjaer S, Bitsch-Larsen D, Andersen O: Hepatic failure in a child after acetaminophen and sevoflurane exposure. Anesth Analg 92:1446–1448, 2001.

174. Frink EJ Jr, Ghantous H, Malan TP, et al: Plasma inorganic fluoride with sevoflurane anesthesia: Correlation with indices of hepatic and renal function. Anesth Analg 74:231–235, 1992.

175. Ray DC, Bomont R, Mizushima A, et al: Effect of sevoflurane anaesthesia on plasma concentrations of glutathione S-transferase. Br J Anaesth 77:404–407, 1996.

176. Taivainen T, Tiainen P, Meretoja OA, et al: Comparison of the effects of sevoflurane and halothane on the quality of anaesthesia and serum glutathione transferase alpha and fluoride in paediatric patients. Br J Anaesth 73:590–595, 1994.

177. Hussey AJ, Aldridge LM, Paul D, et al: Plasma glutathione S-transferase concentration as a measure of hepatocellular integrity following a single general anaesthetic with halothane, enflurane or isoflurane. Br J Anaesth 60:130–135, 1988.

178. Allan LG, Hussey AJ, Howie J, et al: Hepatic glutathione S-transferase release after halothane anaesthesia: Open randomised comparison with isoflurane. Lancet 1:771–774, 1987.

179. Tsujmoto S, Kato H, Minamoto Y, et al: Comparison of postoperative liver dysfunction after halothane and sevoflurane anesthesia in women undergoing mastectomy for cancer. J Anesth 9:129–34, 1995.

180. Lynch S, Martis L, Woods E: Evaluation of hepatoxic potential of sevoflurane in rats. Pharmacologist 21:221, 1979.

181. Joshi PH, Conn HO: The syndrome of methoxyflurane-associated hepatitis. Ann Intern Med 80:395–401, 1974.

182. Martin JL: Halothane hepatitis: A possible immune-mediated hepatitis. In Newcombe DS, Rose NR, Bloom JC (eds): Halothane Hepatitis: A Possible Immune Mediated Hepatitis. New York, Raven Press, 1992, pp 155–175.

268

183. Bottiger LE, Dalen E, Hallen B: Halothane-induced liver damage: An analysis of the material reported to the Swedish Adverse Drug Reaction Committee, 1966–1973. Acta Anaesthesiol Scand 20:40–46, 1976.

184. Walton B, Simpson BR, Strunin L, et al: Unexplained hepatitis following halothane. Br Med J 1:1171–1176, 1976.

185. Takagi T, Ishii H, Takahashi H, et al: Potentiation of halothane hepatotoxicity by chronic ethanol administration in rat: An animal model of halothane hepatitis. Pharmacol Biochem Behav 18(Suppl 1):461–465, 1983.

186. Ryan DE, Koop DR, Thomas PE, et al: Evidence that isoniazid and ethanol induce the same microsomal cytochrome P-450 in rat liver, an isozyme homologous to rabbit liver cytochrome P-450 isozyme 3a. Arch Biochem Biophys 246:633–644, 1986.

187. Thomas PE, Bandiera S, Maines SL, et al: Regulation of cytochrome P-450j, a high-affinity N-nitrosodimethylamine demethylase, in rat hepatic microsomes. Biochemistry 26:2280–2289, 1997.

188. Gruenke LD, Konopka K, Koop DR, Waskell LA: Characterization of halothane oxidation by hepatic microsomes and purified cytochromes P-450 using a gas chromatographic mass spectrometric assay. J Pharmacol Exp Ther 246:454–459, 1988.

189. Carey RMT, Van Dyke RA: Halothane hepatitis: A critical review. Anesth Analg 51:135–160, 1972.

190. Nimmo WS, Thompson PG, Prescott LF: Microsomal enzyme induction after halothane anaesthesia. Br J Clin Pharmacol 12:433–434, 1981.

191. Cohen EN, Hood N: Application of low-temperature autoradiography to studies of the uptake and metabolism of volatile anesthetics in the mouse. 3. Halothane. Anesthesiology 31:553–559, 1969.

192. Cohen EN: Metabolism of the volatile anesthetics. Anesthesiology 35:193–202, 1971.

193. Cascorbi HF, Vesell ES, Blake DA, Helrich M: Halothane biotransformation in man. Ann N Y Acad Sci 179:244–248, 1971.

194. Plummer JL, Steven IM, Cousins MJ: Metabolism of halothane in children having repeated halothane anaesthetics. Anaesth Intensive Care 15:136–140, 1987.

195. Stenger RJ, Johnson EA: Effects of phenobarbital pretreatment on the response of rat liver to halothane administration. Proc Proc Soc Exp Bill Med 140:1319–1324, 1972.

196. Hoft RH, Bunker JP, Goodman HI, Gregory PB: Halothane hepatitis in three pairs of closely related women. N Engl J Med 304:1023–1024, 1981.

197. Farrell G, Prendergast D, Murray M: Halothane hepatitis. Detection of a constitutional susceptibility factor. N Engl J Med 313:1310–1314, 1985.

198. Carney FM, Van Dyke RA: Halothane hepatitis: A critical review. Anesth Analg 51:135–160, 1972.

199. Inman WH, Mushin WW: Jaundice after repeated exposure to halothane: An analysis of reports to the committee on safety of medicines. Br Med J 1:5–10, 1974.

200. Cousins MJ, Plummer JL, Hall PD: Risk factors for halothane hepatitis. Aust N Z J Surg 59:5–14, 1989.

201. Peters RL, Edmondson HA, Reynolds TB, et al: Hepatic necrosis associated with halothane anesthesia. Am J Med 47:748–764, 1969.

202. Kenna JG, Neuberger J, Williams R: An enzyme-linked immunosorbent assay for detection of antibodies against halothane-altered hepatocyte antigens. J Immunol Methods 75:3–14, 1984.

203. Kenna JG, Neuberger J, Williams R: Specific antibodies to halothane-induced liver antigens in halothane-associated hepatitis. Br J Anaesth 59:1286–1290, 1987.

204. Nomura F, Hatano H, Ohnishi K, et al: Effects of anticonvulsant drugs on halothane-induced liver injury in human subjects and experimental animals. Hepatology 6:952–956, 1986.

205. Hubbard AK, Roth TP, Gandolfi AJ, et al: Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane. Anesthesiology 68:791–796, 1988.

206. Martin JL, Kenna JG, Pohl LR: Antibody assays for the detection of patients sensitized to halothane. Anesth Analg 70:154–159, 1990.

207. Satoh H, Gillette JR, Takemura T, et al: Investigation of the immunological basis of halothane-induced hepatotoxicity. In Kocsis JI, Jollow DJ, Witmer CM, et al (eds): Biological Reactive Intermediates. New York, Plenum, 1988, pp. 657–673.

208. Crandell WB, Pappas SG, Macdonald A: Nephrotoxicity associated with methoxyflurane anesthesia. Anesthesiology 27:591–607, 1969.

209. Mazze RI, Shue GL, Jackson SH: Renal dysfunction associated with methoxyflurane anesthesia. A randomized, prospective clinical evaluation. JAMA 216:278–288, 1971.

210. Mazze RI, Cousins MJ, Kosek JC: Dose-related methoxyflurane nephrotoxicity in rats: A biochemical and pathologic correlation. Anesthesiology 36:571–587, 1972.

211. Njoku DB: Effects of halogenated inhalation agents on the liver and kidneys. Probl Anesth Curr Issues Pediatr Anesth 10:478–487, 2000.

212. Whitford GM, Taves DR: Fluoride-induced diuresis: Renaltissue solute concentrations, functional, hemodynamic, and histologic correlates in the rat. Anesthesiology 39:416–427, 1973.

213. Kharasch ED, Hankins DC, Thummel KE: Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 82:689–699, 1995.

214. Cousins MJ, Mazze RI, Kosek JC, et al: The etiology of methoxyflurane nephrotoxicity. J Pharmacol Exp Ther 190:530–541, 1974.

215. Smith FA (ed): Handbook of Experimental Pharmacology. Pharmacology of Fluorides. New York, Springer-Verlag, 1970.

216. Van Dyke RA: Enflurane, isoflurane, and methoxyflurane metabolism in rat hepatic microsomes from ethanol-treated animals. Anesthesiology 58:221–224, 1983.

217. Rice SA, Dooley JR, Mazze RI: Metabolism by rat hepatic microsomes of fluorinated ether anesthetics following ethanol consumption. Anesthesiology 58:237–241, 1983.

218. Biermann JS, Rice SA, Gallagher EJ, West JA: Effect of diazepam treatment on hepatic microsomal anesthetic defluorinase activity. Arch Intern Pharmacodyn Ther 283:181–192, 1986.

219. Mazze RI, Cousins MJ: Combined nephrotoxicity of gentamicin and methoxyflurane anaesthesia in man. A case report. Br J Anaesth 45:394–398, 1973.

220. Barr GA, Mazze RI, Cousins MJ, Kosek JC: An animal model for combined methoxyflurane and gentamicin nephrotoxicity. Br J Anaesth 45:306–312, 1973.

221. Cousins MJ, Greenstein LR, Hitt BA, Mazze RI: Metabolism and renal effects of enflurane in man. Anesthesiology 44:44–53, 1976.

222. Mazze RI, Sievenpiper TS, Stevenson J: Renal effects of enflurane and halothane in patients with abnormal renal function. Anesthesiology 60:161–163, 1984.

223. Mazze RI, Calverley RK, Smith NT: Inorganic fluoride nephrotoxicity: Prolonged enflurane and halothane anesthesia in volunteers. Anesthesiology 46:265–271, 1977.

224. Sievenpiper TS, Rice SA, McClendon F, et al: Renal effects of enflurane anesthesia in Fischer 344 rats with pre-existing renal insufficiency. J Pharmacol Exp Ther 211:36–41, 1979.

225. Fish K, Sievenpiper T, Rice SA, et al: Renal function in Fischer 344 rats with chronic renal impairment after administration of enflurane and gentamicin. Anesthesiology 53:481–488, 1980.

226. Bentley JB, Vaughan RW, Miller MS, et al: Serum inorganic fluoride levels in obese patients during and after enflurane anesthesia. Anesth Analg 58:409–412, 1979.

227. Rice SA, Fish KJ: Anesthetic metabolism and renal function in obese and nonobese Fischer 344 rats following enflurane or isoflurane anesthesia. Anesthesiology 65:28–34, 1986.

228. Rice SA, Sbordone L, Mazze RI: Metabolism by rat hepatic microsomes of fluorinated ether anesthetics following isoniazid administration. Anesthesiology 53:489–493, 1980.

269

229. Mazze RI, Woodruff RE, Heerdt ME: Isoniazid-induced enflurane defluorination in humans. Anesthesiology 57:5–8, 1982.

230. Cousins MI, Mazze RI: Methoxyflurane nephrotoxicity: A study of dose response in man. JAMA 225:1611, 1973.

231. Murray JM, Trinick TR: Plasma fluoride concentrations during and after prolonged anesthesia: A comparison of halothane and isoflurane. Anesth Analg 74:236–240, 1992.

232. Mazze RI, Cousins MJ, Barr GA: Renal effects and metabolism of isoflurane in man. Anesthesiology 40:536, 1974.

233. Arnold JH, Truog RD, Rice SA: Prolonged administration of isoflurane to pediatric patients during mechanical ventilation. Anesth Analg 76:520–526, 1993.

234. Nuscheler M, Conzen P, Peter K: Sevoflurane: Metabolism and toxicity. Anaesthesist 47(Suppl 1):S24–S32, 1998.

235. Kobayashi Y, Ochiai R, Takeda J, et al: Serum and urinary inorganic fluoride concentrations after prolonged inhalation of sevoflurane in humans. Anesth Analg 74:753–757, 1992.

236. Rice SA, Sbordone L, Mazze RI: Metabolism by rat hepatic microsomes of fluorinated ether anesthetics following isoniazid administration. Anesthesiology 53:489–493, 1980.

237. Truog RD, Rice SA: Inorganic fluoride and prolonged isoflurane anesthesia in the intensive care unit. Anesth Analg 69:843, 1989.

238. Hara T, Fukusaki M, Nakamura T, Sumikawa K: Renal function in patients during and after hypotensive anesthesia with sevoflurane. J Clin Anesth 10:539–545, 1998.

239. Frink EJ, Malan TP, Isner J, et al: Renal concentrating function with prolonged sevoflurane or enflurane anesthesia in volunteers. Anesthesiology 80:1019, 1994.

240. Higuchi H, Arimura S, Sumikura H, et al: Urine concentrating ability after prolonged sevoflurane anesthesia. Br J Anaesth 73:239–240, 1994.

241. Groudine SB, Fragen RJ, Kharasch ED, et al: Comparison of renal function following anesthesia with low-flow sevoflurane and isoflurane. J Clin Anesth 11:201–207, 1999.

242. Bito H, Ikeda K: Long-duration, low-flow sevoflurane anesthesia using two carbon dioxide absorbents: Quantification of degradation products in the circuit. Anesthesiology 81:340–345, 1994.

243. Artu AA: Renal effects of sevoflurane during conditions of possible increased risk. J Clin Anesth 10:531–538, 1998.

244. Avery T, Jacobsohn E: A case of nonoliguric renal failure after general anesthesia with sevoflurane and desflurane. Anesth Analg 85:1407–1409, 1997.

245. Mori N, Nagata H, Ohta S, Suzuki M: Prolonged sevoflurane inhalation was not nephrotoxic in two patients with refractory status asthmaticus. Anesth Analg 83:189–191, 1996.

246. Conzen PF, Nuscheler M, Melotte A, et al: Renal function and serum fluoride concentrations in patients with stable renal insufficiency after anesthesia with sevoflurane or enflurane. Anesth Analg 81:569–575, 1995.

247. Tsukamoto N, Hirabayashi Y, Shimizu R, Mitsuhata H: The effects of sevoflurane and isoflurane anesthesia on renal tubular function in patients with moderately impaired renal function. Anesth Analg 82:909–913, 1996.

248. Morita K, Otsuka F, Ogura T, et al: Sevoflurane anaesthesia causes a transient decrease in aquaporin-2 and impairment of urine concentration. Br J Anaesth 83:734–739, 1999.

249. Smiley RM, Ornstein E, Pantuck EJ, et al: Metabolism of desflurane and isoflurane to fluoride ion in surgical patients. Can J Anaesth 38:965–968, 1991.

250. Bito H, Ikeda K: Closed-circuit anesthesia with sevoflurane in humans: Effects on renal and hepatic function and concentrations of breakdown products with soda lime in the circuit. Anesthesiology 80:71–76, 1994.

251. Cunningham DD, Huang S, Webster J, et al: Sevoflurane degradation to compound A in anaesthesia breathing systems. Br J Anaesth 77:537–543, 1996.

252. Bito H, Ikeda K: Degradation products of sevoflurane during low-flow anaesthesia. Br J Anaesth 74:56–59, 1995.

253. Gonoswski BS, Laster MJ, Eger EI, et al: Toxicity of compound A in rats. Anesthesiology 80:550–565, 1994.

254. Keller KA, Callan C, Prokocimer P, et al: Inhalation toxicity study of a haloalkene degradant of sevoflurane, compound A (PIFE), in Sprague-Dawley rats. Anesthesiology 83:1220–1232, 1995.

255. Gonoswski BS, Laster MJ, Eger EI, et al: Toxicity of compound A in rats. Anesthesiology 80:566–573, 1994.

256. Bito H, Ikeda K: Plasma inorganic fluoride and intracircuit degradation product concentrations in long-duration, low-flow sevoflurane anesthesia. Anesth Analg 79:946–951, 1994.

257. Frink EJ Jr, isner RJ, Malan TP Jr, et al: Sevoflurane degradation product concentrations with soda lime during prolonged anesthesia. J Clin Anesth 6:239–242, 1994.

258. Bito H, Ikeda K: Renal and hepatic function in surgical patients after low-flow sevoflurane or isoflurane anesthesia. Anesth Analg 82:173–176, 1996.

259. Mazze RI, Callan CM, Galvez ST, et al: The effects of sevoflurane on serum creatinine and blood urea nitrogen concentrations: A retrospective, twenty-two-center, comparative evaluation of renal function in adult surgical patients. Anesth Analg 90:683–688, 2000.

260. Kharasch ED, Frink EJ Jr, Artru A, et al: Long-duration low-flow sevoflurane and isoflurane effects on postoperative renal and hepatic function. Anesth Analg 93:1511–1520, 2001.

261. Mazze RI, Jamison RL: Low-flow (1 L/min) sevoflurane: Is it safe? Anesthesiology 86:1225–1227, 1997.

262. Kumano H, Osaka S, Ishimura N, Nishiwada M: [Effects of enflurane, isoflurane, and sevoflurane on renal tubular functions.] Masui 41:1735–1740, 1992.

263. Bito H, Ikeuchi Y, Ikeda K: Effects of low-flow sevoflurane anesthesia on renal function: Comparison with high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia. Anesthesiology 86:1231–1237, 1997.

264. Kharasch ED, Frink EJ Jr, Zager R, et al: Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. Anesthesiology 86:1238–1253, 1997.

265. Nishiyama T, Hanaoka K: Inorganic fluoride kinetics and renal and hepatic function after repeated sevoflurane anesthesia. Anesth Analg 87:468–473, 1998.

266. Eger EI, Koblin DD, Bowland T, et al: Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg 84:160–168, 1997.

267. Ebert TJ, Frink EJ Jr, Kharasch ED: Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers. Anesthesiology 88:601–610, 1998.

268. Goldberg ME, Cantillo J, Gratz I, et al: Dose of compound A, not sevoflurane, determines changes in the biochemical markers of renal injury in healthy volunteers. Anesth Analg 88:437–445, 1999.

269. Higuchi H, Wada H, Usui Y, et al: Effects of probenecid on renal function in surgical patients anesthetized with low-flow sevoflurane. Anesthesiology 94:21–31, 2001.

270. Higuchi H, Sumita S, Wada H, et al: Effects of sevoflurane and isoflurane on renal function and on possible markers of nephrotoxicity. Anesthesiology 89:307–322, 1998.

271. Eger EI, Gong D, Koblin DD, et al: Dose-related biochemical markers of renal injury after sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg 85:1154–1163, 1997.

272. Ebert TJ, Messana LD, Uhrich TD, Staacke TS: Absence of renal and hepatic toxicity after four hours of 1.25 minimum alveolar anesthetic concentration sevoflurane anesthesia in volunteers. Anesth Analg 86:662–667, 1998.

273. Levine MF, Sarner J, Lerman J, et al: Plasma inorganic fluoride concentrations after sevoflurane anesthesia in children. Anesthesiology 84:348–353, 1996.

274. Frink EJ Jr, Green WB Jr, Brown EA, et al: Compound A concentrations during sevoflurane anesthesia in children. Anesthesiology 84:566–571, 1996.

275. Payne AK, Morgan SE, Gandolfi AJ, Brendel K: Biotransformation of sevoflurane by rat neonate liver slices. Drug Metab Dispos 23:497–500, 1995.

276. Iyer RA, Anders MW: Cysteine conjugate beta-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product compound A in human, nonhuman primate, and rat kidney cytosol and mitochondria. Anesthesiology 85:1454–1461, 1996.

270

277. Spracklin DK, Kharasch ED: Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase. Chem Res Toxicol 9:696–702, 1996.

278. Jin L, Baillie TA, Davis MR, Kharasch ED: Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: Evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase. Biochem Biophys Res Commun 210:498–506, 1995.

279. Jin L, Davis MR, Kharasch ED, et al: Identification in rat bile of glutathione conjugates of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane. Chem Res Toxicol 9:555–561, 1996.

280. Commandeur JN, Oostendorp RA, Schoofs PR, et al: Nephrotoxicity and hepatotoxicity of 1,1-dichloro-2,2-difluoroethylene in the rat. Indications for differential mechanisms of bioactivation. Biochem Pharmacol 36:4229–4237, 1987.

281. Vamvakas S, Kremling E, Dekant W: Metabolic activation of the nephrotoxic haloalkene 1,1,2-trichloro-3,3,3-trifluoro-1-propene by glutathione conjugation. Biochem Pharmacol 38:2297–2304, 1989.

282. Green T, Odum J, Nash JA, Foster JR: Perchloroethylene-induced rat kidney tumors: An investigation of the mechanisms involved and their relevance to humans. Toxicol Appl Pharmacol 103:77–89, 1990.

283. Iyer RA, Frink EJ Jr, Ebert TJ, Anders MW: Cysteine conjugate beta-lyase-dependent metabolism of compound A (2-[fluoromethoxy]-1,1,3,3,3-pentafluoro-1-propene) in human subjects anesthetized with sevoflurane and in rats given compound A. Anesthesiology 88:611–618, 1998.

284. Iyer RA, Baggs RB, Anders MW: Nephrotoxicity of the glutathione and cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A) in male Fischer 344 rats. J Pharmacol Exp Ther 283:1544–1551, 1997.

285. Kharasch ED, Thorning D, Garton K, et al: Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats. Anesthesiology 86:160–171, 1997.

286. Martin JL, Laster MJ, Kandel L, et al: Metabolism of compound A by renal cysteine-S-conjugate beta-lyase is not the mechanism of compound A-induced renal injury in the rat. Anesth Analg 82:770–774, 1996.

287. Kharasch ED, Hoffman GM, Thorning D, et al: Role of cysteine conjugate β-lyase pathway in inhaled compound A nephrotoxicity in rats. Anesthesiology 88:1624–1633, 1998.

288. Higuchi H, Adachi Y, Wada H, et al: The effects of low-flow sevoflurane and isoflurane anesthesia on renal function in patients with stable moderate renal insufficiency. Anesth Analg 92:650–655, 2001.

289. Conzen PF, Kharasch ED, Czerner SF, et al: Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency. Anesthesiology 97:578–584, 2002.

290. Eger EI, Ionescu P, Laster MJ, et al: Quantitative differences in the production and toxicity of CF₂ =BrCl versus CH₂ F-O-C(=CF₂ )(FC₃ ) (compound A): The safety of halothane does not indicate the safety of sevoflurane. Anesth Analg 85:1164–1170, 1997.

291. Moon RE: Cause of CO poisoning, relation to halogenated agents still not clear. J Clin Monit 11:67–71, 1995.

292. Woehlck HJ, Dunning M III, Connolly LA: Reduction in the incidence of carbon monoxide exposures in humans undergoing general anesthesia. Anesthesiology 87:228–234, 1997.

293. Berry PD, Sessler DI, Larson MD: Severe carbon monoxide poisoning during desflurane anesthesia. Anesthesiology 90:613–616, 1999.

294. Lentz RE: Carbon monoxide poisoning during anesthesia poses puzzles. J Clin Monit 11:66–67, 1995.

295. Baum J, Sachs G, vd Driesch C, Stanke HG: Carbon monoxide generation in carbon dioxide absorbents. Anesth Analg 81:144–146, 1995.

296. Davies MW, Potter FA: Carbon monoxide, soda lime and volatile agents. Anaesthesia 51:90, 1996.

297. Strum DP, Eger EI: The degradation, absorption, and solubility of volatile anesthetics in soda lime depend on water content. Anesth Analg 78:340–348, 1994.

298. Wissing H, Kuhn I, Warnken U, Dudziak R: Carbon monoxide production from desflurane, enflurane, halothane, isoflurane, and sevoflurane with dry soda lime. Anesthesiology 95:1205–1212, 2001.

299. Baxter PJ, Garton K, Kharasch ED: Mechanistic aspects of carbon monoxide formation from volatile anesthetics. Anesthesiology 89:929–941, 1998.

300. Stabernack CR, Brown R, Laster MJ, et al: Absorbents differ enormously in their capacity to produce compound A and carbon monoxide. Anesth Analg 90:1428–1435, 2000.